British PM braces for “partygate” report as England scraps indoor mask requirements and vaccine passports; Moderna follows Pfizer in launching trial to target Omicron
Moderna Inc says it has started a mid-stage study, testing a booster dose of its Covid-19 vaccine specifically designed to target the Omicron variant, a day after rival Pfizer Inc launched a similar trial. The pharmaceutical company said while a third shot of its original coronavirus vaccine increased neutralising antibodies against the variant at the lower dose, their levels declined six months after the booster dose was administered.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: